Nektar Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.05.17	Hennessy Advisors, Inc. to Acquire the Rainier U.S. Equity Funds (PR Newswire)
10.05.17	EARNINGS SUMMARY: Details of Nektar Therapeutics Q1 Earnings Report (RTTNews)
09.05.17	Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 (PR Newswire)
03.05.17	Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program (PR Newswire)
20.04.17	Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting (PR Newswire)
04.04.17	Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
27.03.17	Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders (PR Newswire)
21.03.17	PTIE Surges After-hours, Valeant Gets FDA Date, JAZZ Hits Right Notes (RTTNews)
21.03.17	Gainers & Losers Of Mar.20.: ESPR, NKTR, CTMX, CERU, GNMX... (RTTNews)
20.03.17	Nektar Therapeutics Posting Substantial Gain In Afternoon Trading (RTTNews)
20.03.17	Nektar: NKTR-181 Meets Primary, Secondary Goals In Phase 3 Chronic Pain Study (RTTNews)
20.03.17	NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain (PR Newswire)
13.03.17	Technical Reports on Biotech Stocks -- Nektar Therapeutics, Seattle Genetics, Dynavax Technologies, and BioMarin Pharma (PR Newswire)
05.03.17	What Awaits These 10 Biotech Stocks In March? (RTTNews)
03.03.17	Nektar to Webcast Presentation at Cowen and Company's 37th Annual Health Care Conference in Boston (PR Newswire)
01.03.17	Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting (PR Newswire)
01.03.17	EARNINGS SUMMARY: Details of Nektar Therapeutics Q4 Earnings Report (RTTNews)
01.03.17	Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results (PR Newswire)
22.02.17	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets (PR Newswire)
19.02.17	Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium (PR Newswire)
27.12.16	Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings (PR Newswire)
27.12.16	Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings (PR Newswire)
30.11.16	PrivacyStar iPhone App Now Automatically Blocks Unwanted Calls (PR Newswire)
22.11.16	Biotech Stocks on Investors' Radar -- Vertex Pharma, Nektar Therapeutics, CTI BioPharma, and Sage Therapeutics (PR Newswire)
03.11.16	EARNINGS SUMMARY: Details of Nektar Therapeutics Q3 Earnings Report (RTTNews)
27.09.16	Bristol-Myers, Nektar Collaborate To Evaluate Combination Of Opdivo And NKTR-214 (RTTNews)
03.08.16	EARNINGS SUMMARY: Details of Nektar Therapeutics Q2 Earnings Report (RTTNews)
01.06.16	Nektar And Daiichi Sankyo Europe Sign European Licensing Deal For ONZEALD (RTTNews)
03.05.16	EARNINGS SUMMARY: Details of Nektar Therapeutics Q1 Earnings Report (RTTNews)
18.04.16	Nektar Therapeutics Announces Pre-clinical Data On NKTR-214 (RTTNews)
01.03.16	EARNINGS SUMMARY: Details of Nektar Therapeutics Q4 Earnings Report (RTTNews)
05.11.15	EARNINGS SUMMARY: Details of Nektar Therapeutics Q3 Earnings Report (RTTNews)
07.10.15	Nektar Submits Investigational New Drug Application For NKTR-214 - Quick Facts (RTTNews)
01.09.15	Nektar Receives Milestone Payment On First Sale Of MOVENTIG In Germany (RTTNews)
05.08.15	Nektar Therapeutics Q2 Loss Widens (RTTNews)
30.04.15	Nektar Therapeutics Reports Profit In Q1 - Quick Facts (RTTNews)
17.04.15	SSH Shines, First Generic MS Drug Approved, MNOV On Fast Track, ALDX On Watch (RTTNews)
16.04.15	Baxter Submits New Drug Application To Japan's MHLW For Approval Of BAX 855 (RTTNews)
02.04.15	Nektar Receives $100 Mln Milestone Payment From AstraZeneca For Movantik Sales (RTTNews)
25.02.15	Nektar Starts Phase3 SUMMIT-07 Study Of NKTR-181 In Patients With CLow Back Pain (RTTNews)
25.02.15	ADMP Proves A Point, PETX Regains Drug Rights, CBAY Dips, NKTR On Watch (RTTNews)
25.02.15	Nektar Therapeutics Surge 5% As Q4 Results Top Estimates. Loss Narrows (RTTNews)
24.02.15	Nektar Therapeutics Reports Narrower Than Estimated Q4 Loss (RTTNews)
22.02.15	Will The Beacon Light Up Nektar? (RTTNews)
09.12.14	Nektar Therapeutics Reports Approval Of MOVENTIG In EU - Quick Facts (RTTNews)
29.09.14	AMBI Snapped Up, ALIM's Iluvien Gets FDA Nod, GLYC Faces Glitch In Study (RTTNews)
26.09.14	Nektar Therapeutics Says Moventig Gets Positive CHMP Opinion In EU (RTTNews)
01.08.14	Nektar Therapeutics Q2 Loss Narrows (RTTNews)
31.05.14	Nektar Therapeutics: NKTR-102 Exceeds Primary Endpoint In Phase 2 Study (RTTNews)
07.05.14	Nektar Therapeutics Loss Narrows On Lower Expenses - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18.12.24		Schwacher Handel in New York: NASDAQ Composite implodiert letztendlich nahezu
04.12.24		Freundlicher Handel: NASDAQ Composite am Mittag im Plus
03.12.24		Aufschläge in New York: NASDAQ Composite beendet den Handel mit Gewinnen
27.11.24		Handel in New York: NASDAQ Composite verbucht am Mittwochnachmittag Abschläge
22.11.24		Börse New York: NASDAQ Composite stärker
22.11.24		Starker Wochentag in New York: Zum Handelsstart Gewinne im NASDAQ Composite
15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
15.11.24		Zurückhaltung in New York: NASDAQ Composite verbucht nachmittags Verluste

18.12.24

Schwacher Handel in New York: NASDAQ Composite implodiert letztendlich nahezu

04.12.24

Freundlicher Handel: NASDAQ Composite am Mittag im Plus

03.12.24

Aufschläge in New York: NASDAQ Composite beendet den Handel mit Gewinnen

27.11.24

Handel in New York: NASDAQ Composite verbucht am Mittwochnachmittag Abschläge

22.11.24

Börse New York: NASDAQ Composite stärker

22.11.24

Starker Wochentag in New York: Zum Handelsstart Gewinne im NASDAQ Composite